• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

molecular therapeutics

Pharma & Human Health

Symbiotix Biotherapies Announces License Agreement with Harvard University

March 21, 2018 Microbiome Times

Symbiotix Biotherapies, Inc. (“Symbiotix”), a pioneering venture-backed microbiome company developing novel molecular therapeutics based on the human microbiome, today announced that it has entered into a license agreement with Harvard University. Under the agreement, Symbiotix […]

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
  • Mental Health and the Brain-Gut-Microbiota Axis: Fundamental Importance of Diet
    April 3, 2025
  • Novel In vitro Model Replicates Intestinal Microbiota Composition Without Requiring Anaerobic Incubation
    March 25, 2025
  • Dynamic Microbiome Abundance Profiling: A new tool to solve challenges in microbiome analysis
    March 5, 2025
  • Scientists decode diet from stool DNA – no questions asked
    February 24, 2025
sign up

Sign up to the Microbiome Times newsletter